期刊文献+

紫杉醇脂质体治疗乳腺癌64例分析 被引量:8

Paclitaxel Liposomes Treatment of Breast Cancer(Report of 64 Cases)
在线阅读 下载PDF
导出
摘要 目的 比较注射用紫杉醇脂质体与紫杉醇注射液治疗晚期乳腺癌的近期疗效及不良反应的差别。 方法 采用多中心、单盲、随机对照的方法进行研究。晚期乳腺癌患者 6 4例随机分为对照组和试验组。试验组 (33例 ) :紫杉醇脂质体 135 mg/ m2 ,3h静滴 ,阿霉素 (4 0 mg/ m2 )或表阿霉素 (6 0 mg/ m2 ) ,静推 ,每 3周重复 ;对照组 (31例 ) :紫杉醇注射液代替紫杉醇脂质体 ,余同试验组。 结果 试验组和对照组总有效率分别为 4 5 .5 %和 4 3.3% ,(P >0 .0 5 )。主要不良反应分别是 :白细胞减少、血小板减少、血红蛋白降低等 ;除皮疹外两组不良反应发生率无明显差异。 结论 两种紫杉醇的疗效相当 ,但其溶媒所产生的皮疹等过敏反应 ,紫杉醇脂质体明显低于紫杉醇注射液 。 Objective To compare the difference between paclitaxel and paclitaxel liposomes in the efficacy and toxicity for treatment of advanced breast cancer. Methods The multicenter mono\|blindness randomized control investigation methods was used. Trial group: paclitaxel liposomes injection 135 mg/m\+2 iv for 3 hours and adriamycin(ADM) 40 mg/m\+2 or epirubicin(E\|ADM) 60 mg/m\+2 administered every 3 weeks for 2 cycles. Control group: the paclitaxel injection instead of paclitaxel liposomes, the rest was same to the trial group. Results 64 cases of pathologically confirmed and measurable metastatic adenocarcinoma of the breast were enrolled. The overall response(OR) rate of the trial group and control group were 45 5% and 43 3%, respectively(P>0 05). The toxicity of the trial group and control group included: leukopenia, thrombocytopenia, anemia, GPT and GOT elevation, dyspnea, nausea or vomiting, diarrhea, alopecia, flush of face, anorexia, abdominal pain, fatigue, arthralgia, muscle pain(P>0 05) and skin eruption. Conclusion This two kinds of paclitaxel are a efficient regiment for breast cancer \{alike\}. The incidence of skin eruption of paclitaxel liposomes is lower than paclitaxe, the rest of the toxicity of this tow groups are similar.
出处 《福建医科大学学报》 2003年第2期193-195,共3页 Journal of Fujian Medical University
关键词 乳腺肿瘤 紫杉酚 breast neoplasm paclitaxel
  • 相关文献

参考文献10

  • 1孙燕.临床肿瘤学手册[M].北京:北京医科大学,中国协和医科大学联合出版社,1992.157.
  • 2林李嵩,林国础,陈万涛,周晓健.紫杉醇对ACC-2细胞的体外抗增殖作用[J].福建医科大学学报,2001,35(3):241-243. 被引量:2
  • 3Dombernowsky P,Gehl J, Boesgaard M ,et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast carcer[J]. Semin Oncot, 1996, 23 (Suppl 11):23-27.
  • 4Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, et al.Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase Ⅱ study conducted by the Hellenic Cooperative Oncology Group[J]. Eur J Cancer,1997,33,1893-1895.
  • 5Donebower RC,Rowinsky EK. Paclitaxel[J]. PPO updates,1994,8:5-8.
  • 6Straubinger RM,Sharma A,Muray M,et al. Novel taxol formulations,taxol-containing liposomes[J]. J Nail Cancer Inst Monoger, 1993,15 : 69-78.
  • 7Sharma A,Mayhew E,Bolicsak L,et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografta[J]. Int J Cancer, 1997,71,103-107.
  • 8Cabanes A,Briggs KE,Gokhale PC,et al. Comparative in vivo studies with paclitaxel and liposome encapsulated paclitaxel[J]. Int J Oncol, 1998,12:1035-1040.
  • 9Rowwinsky EK,Eiscnhauer EA,Chaudhry V,et aL Clinical toxicities encountered with taxol[J]. Semin Oncol, 1993,20:1-13.
  • 10Holmes FA,Wslters RS,Thrisult RL,et al. Phase Ⅱ trial of taxolan active drug in metastatic breast cancer[J]. J Natl Cancer Inst, 1991,83 :1797-1805.

二级参考文献2

共引文献15

同被引文献57

引证文献8

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部